Free Trial

Benitec Biopharma (BNTC) Competitors

Benitec Biopharma logo
$14.01 -0.66 (-4.50%)
Closing price 03/26/2025 04:00 PM Eastern
Extended Trading
$14.10 +0.09 (+0.61%)
As of 03/26/2025 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BNTC vs. ETNB, ADPT, EVO, SPRY, ARDX, OCUL, GPCR, CALT, IOVA, and SNDX

Should you be buying Benitec Biopharma stock or one of its competitors? The main competitors of Benitec Biopharma include 89bio (ETNB), Adaptive Biotechnologies (ADPT), Evotec (EVO), ARS Pharmaceuticals (SPRY), Ardelyx (ARDX), Ocular Therapeutix (OCUL), Structure Therapeutics (GPCR), Calliditas Therapeutics AB (publ) (CALT), Iovance Biotherapeutics (IOVA), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "pharmaceutical products" industry.

Benitec Biopharma vs.

Benitec Biopharma (NASDAQ:BNTC) and 89bio (NASDAQ:ETNB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, community ranking, earnings and profitability.

Benitec Biopharma has higher revenue and earnings than 89bio. Benitec Biopharma is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Benitec Biopharma$80K4,106.86-$21.75M-$1.51-9.28
89bioN/AN/A-$142.19M-$3.43-2.34

In the previous week, Benitec Biopharma had 5 more articles in the media than 89bio. MarketBeat recorded 11 mentions for Benitec Biopharma and 6 mentions for 89bio. Benitec Biopharma's average media sentiment score of 0.70 beat 89bio's score of 0.52 indicating that Benitec Biopharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Benitec Biopharma
3 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
89bio
0 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Benitec Biopharma has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500. Comparatively, 89bio has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500.

Benitec Biopharma's return on equity of -44.61% beat 89bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Benitec BiopharmaN/A -44.61% -41.25%
89bio N/A -59.58%-52.21%

52.2% of Benitec Biopharma shares are owned by institutional investors. 1.3% of Benitec Biopharma shares are owned by company insiders. Comparatively, 2.8% of 89bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Benitec Biopharma received 82 more outperform votes than 89bio when rated by MarketBeat users. Likewise, 65.55% of users gave Benitec Biopharma an outperform vote while only 63.33% of users gave 89bio an outperform vote.

CompanyUnderperformOutperform
Benitec BiopharmaOutperform Votes
196
65.55%
Underperform Votes
103
34.45%
89bioOutperform Votes
114
63.33%
Underperform Votes
66
36.67%

Benitec Biopharma currently has a consensus target price of $24.43, indicating a potential upside of 74.37%. 89bio has a consensus target price of $27.56, indicating a potential upside of 243.59%. Given 89bio's higher probable upside, analysts clearly believe 89bio is more favorable than Benitec Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Benitec Biopharma
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
2 Strong Buy rating(s)
3.22
89bio
0 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.90

Summary

Benitec Biopharma beats 89bio on 12 of the 16 factors compared between the two stocks.

Remove Ads
Get Benitec Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BNTC vs. The Competition

MetricBenitec BiopharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$328.55M$6.90B$5.62B$8.13B
Dividend YieldN/A2.73%4.56%4.00%
P/E Ratio-9.287.1824.5419.09
Price / Sales4,106.86226.87384.9694.71
Price / CashN/A65.6738.1634.64
Price / Book4.326.486.934.36
Net Income-$21.75M$142.41M$3.20B$247.23M
7 Day Performance-16.56%-2.89%-2.17%-0.32%
1 Month Performance22.79%-4.52%3.15%-3.60%
1 Year Performance173.10%-8.69%11.00%2.01%

Benitec Biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BNTC
Benitec Biopharma
1.8861 of 5 stars
$14.01
-4.5%
$24.43
+74.4%
+182.5%$328.55M$80,000.00-9.2820Analyst Forecast
Short Interest ↑
Gap Up
ETNB
89bio
2.8554 of 5 stars
$9.15
+7.4%
$27.56
+201.2%
-28.4%$1.34BN/A-3.1440
ADPT
Adaptive Biotechnologies
3.3859 of 5 stars
$8.66
+3.1%
$9.40
+8.5%
+186.1%$1.29B$178.96M-7.94790
EVO
Evotec
1.7057 of 5 stars
$3.63
+3.4%
$5.93
+63.5%
-54.2%$1.29B$777.05M0.004,200
SPRY
ARS Pharmaceuticals
3.347 of 5 stars
$12.89
+4.3%
$31.00
+140.5%
+26.0%$1.25B$89.15M-25.2790Earnings Report
Analyst Revision
High Trading Volume
ARDX
Ardelyx
4.3869 of 5 stars
$5.25
+2.3%
$10.95
+108.6%
-32.1%$1.25B$333.62M-32.8190
OCUL
Ocular Therapeutix
3.3732 of 5 stars
$7.62
+1.5%
$16.38
+114.9%
-16.6%$1.21B$63.72M-5.77230Positive News
GPCR
Structure Therapeutics
2.2782 of 5 stars
$21.05
+0.4%
$81.29
+286.2%
-52.6%$1.21BN/A-28.45136
CALT
Calliditas Therapeutics AB (publ)
N/A$40.00
flat
$39.25
-1.9%
N/A$1.19B$1.60B-21.62180
IOVA
Iovance Biotherapeutics
4.319 of 5 stars
$3.63
+2.5%
$20.25
+457.9%
-75.5%$1.19B$164.07M-2.44500Analyst Revision
SNDX
Syndax Pharmaceuticals
3.667 of 5 stars
$13.73
+0.1%
$36.20
+163.7%
-38.8%$1.18B$23.68M-3.78110
Remove Ads

Related Companies and Tools


This page (NASDAQ:BNTC) was last updated on 3/27/2025 by MarketBeat.com Staff
From Our Partners